earnings
confidence high
sentiment negative
materiality 0.85
Rezolute Q2 net loss $22.8M; Phase 3 congenital HI study misses primary endpoint
Rezolute, Inc.
2026-Q2 EPS reported
-$0.40
- Net loss $22.8M vs $15.7M YoY; R&D $14.3M, G&A $9.9M; cash $132.9M down from $167.9M.
- Phase 3 sunRIZE study of ersodetug for congenital HI did not meet primary or key secondary endpoints.
- Reduction in hypoglycemia by CGM was statistically significant at Week 16 but not at Week 24 endpoint.
- FDA meeting planned under Breakthrough Therapy designation before end of Q1 to discuss next steps.
- Enrollment ongoing for tumor HI Phase 3 upLIFT study; topline results expected H2 2026.